Blue-light filtering alters angiogenic signaling in human retinal pigmented epithelial cells culture model

Natalia Vila1,2*, Aya Siblini1, Evangelina Esposito1, Vasco Bravo-Filho1, Pablo Zoroquiain1, Sultan Aldrees1, Patrick Logan1, Lluis Arias2 and Miguel N. Burnier1

Abstract

Background: Light exposure and more specifically the spectrum of blue light contribute to the oxidative stress in Age-related macular degeneration (AMD). The purpose of the study was to establish whether blue light filtering could modify proangiogenic signaling produced by retinal pigmented epithelial (RPE) cells under different conditions simulating risk factors for AMD.

Methods: Three experiments were carried out in order to expose ARPE-19 cells to white light for 48 h with and without blue light-blocking filters (BLF) in different conditions. In each experiment one group was exposed to light with no BLF protection, a second group was exposed to light with BLF protection, and a control group was not exposed to light. The ARPE-19 cells used in each experiment prior to light exposure were cultured for 24 h as follows: Experiment 1) Normoxia, Experiment 2) Hypoxia, and Experiment 3) Lutein supplemented media in normoxia. The media of all groups was harvested after light exposure for sandwich ELISA-based assays to quantify 10 pro-angiogenic cytokines.

Results: A significant decrease in angiogenin secretion levels and a significant increase in bFGF were observed following light exposure, compared to dark conditions, in both normoxia and hypoxia conditions. With the addition of a blue light-blocking filter in normoxia, a significant increase in angiogenin levels was observed. Although statistical significance was not achieved, blue light filters reduce light-induced secretion of bFGF and VEGF to near normal levels. This trend is also observed when ARPE-19 cells are grown under hypoxic conditions and when pre-treated with lutein prior to exposure to experimental conditions.

Conclusions: Following light exposure, there is a decrease in angiogenin secretion by ARPE-19 cells, which was abrogated with a blue light - blocking filter. Our findings support the position that blue light filtering affects the secretion of angiogenic factors by retinal pigmented epithelial cells under normoxic, hypoxic, and lutein-pretreated conditions in a similar manner.

Keywords: Blue light filters, RPE cell line, Angiogenesis, Age-related macular degeneration
Background

Age-related macular degeneration (AMD) is the leading cause of severe and irreversible loss of vision in the elderly in developed countries [1]. AMD is a complex disease associated with many environmental, lifestyle, and genetic factors [2–4]. Although some aspects of AMD pathogenesis are not well understood, there is a growing body of evidence suggesting that oxidative stress can contribute to the onset and progression of the condition [5]. A known cause of such oxidative stress is exposure to short wavelength light, including ultraviolet and blue light.

Blue light exposure has been linked to abnormal secretion of potent pro-angiogenic factors that can promote the onset or progression of ocular diseases with a neo-vascular component. The blue light spectrum of natural sunlight is often cited as the primary cause of blue light-induced damage within the eye. Indeed, data from epidemiologic analyses support this hypothesis: the Beaver Dam Eye Study and the Chesapeake Bay Waterman Study both reported a significant association between cumulative sunlight exposure and AMD [6–9]. Moreover, it has been demonstrated that blue light-induced damage in retinal pigmented epithelial (RPE) cells can promote angiogenic signaling, thereby contributing to an environment that promotes neovascular disease [10].

The mounting evidence that blue light exposure may contribute to the development of AMD has led to the introduction of blue light-filtering intraocular lenses (IOLs) as an alternative to traditional IOL models. Previous studies have shown that blue light-filtering IOLs can mitigate light-induced increases in vascular endothelial growth factor (VEGF) compared with IOLs that only filter ultraviolet (UV) light [11, 12]. The local environment in the macula of patients with non-exudative AMD is known to be hypoxic [13]. Moreover, aging in general has been associated with inflammation and hypoxia in the choriocapillaris, RPE layer, and neurosensory retina [14]. Hypoxia may also be caused by confluent drusen—characteristic feature of AMD—, which can increase the distance between Bruch’s membrane and the RPE and neural retina, thereby impeding oxygen delivery to the latter [4, 15, 16].

Lutein is a well described, naturally occurring macular pigment; high levels of lutein in the macula are known to be protective against AMD [17, 18]. A number of studies—including the Age-Related Eye Disease Study 2 (AREDS2), a large-scale clinical trial—have demonstrated that lutein supplementation may be protective against progression from AMD to a more severe stage of the disease [19]. Recommendations on the heels of AREDS2 have led many clinicians to advise high-risk AMD patients to consume lutein-containing supplements.

Several studies suggest that filtering blue light may reduce oxidative stress and angiogenic signaling in the retina [10–12]; however, whether or not the consequences of such filtering would be altered by a hypoxic environment—such as that seen in the eyes of some AMD patients—are unknown. Similarly, it is not known whether lutein supplementation in high-risk non-exudative AMD patients can alter the well-studied benefits of blue light filtering in AMD patients. Accordingly, the purpose of the current study was to establish the degree to which blue light filtering could affect angiogenic signaling in RPE cells under normoxic, hypoxic, and lutein-treated conditions.

Methods

Three experiments were carried out in order to expose ARPE-19 cells to white light with and without blue light-blocking filters (BLF) in different conditions (normoxia, hyperoxia and lutein pre-treated). Each experiment had one group exposed to light with a BLF protection, a second group exposed to light with no filter protection, and a light-unexposed control group. The ARPE-19 cells used in each experiment prior to light exposure were cultured for 24 h, as described below. The media of all groups was harvested after light exposure to quantify pro-angiogenic cytokines.

Cell culture

The ARPE-19 cell line was obtained from American Type Culture Collection (Manassas, VA, USA). Cells were incubated at 37 °C in a humidified 5% CO₂-enriched atmosphere, and cultured in a 1:1 mixture of Dulbecco’s modified Eagle’s medium (DMEM) and Ham’s F12 medium (ThermoFisher, MA, USA) supplemented with 10% fetal bovine serum (FBS), 1% fungizone, and 1% penicillin-streptomycin. Normal growth was confirmed at every media change by phase contrast microscopy. Cultures were grown to confluence and subcultured using 0.05% trypsin in EDTA (Corning Inc., NY, USA). ARPE-19 cells at passage seven were used in all experiments.

Cells were seeded on 48-well plates at a density of 2.5 × 10⁴ cells/well for all experiments and grown in complete media overnight. The following day, cells were serum-starved and incubated for an additional 24 h in normoxia (experiment 1), hypoxia (experiment 2) or pre-treated with Lutein (experiment 3). Cells were then exposed to light with or without filter. The control plate was wrapped in aluminum foil (dark maintained), while the other two plates were left unwrapped under a light source (light exposed). Supernatants from duplicate wells were pooled and experiments were conducted in triplicate.

Experimental conditions

Experiment 1: Normoxic conditions - Cells were seeded and the following day were serum-starved and incubated under normoxic conditions (37 °C, 5% CO₂) for an additional 24 h before being exposed to light for 48 h.
Experiment 2: Hypoxic conditions - ARPE-19 cell cultures were serum-starved for 24 h and then incubated in 1% O₂. Hypoxia was induced using a Modular Incubator Chamber (Billups-Rothenberg, Inc., San Diego, CA, USA) before being exposed to light. The hypoxic mixture of the certified medical pre-mixed gas used was: 1.00% O₂, 4.98% CO₂ and balance N₂.

Experiment 3: Pre-treatment with lutein - Serum-free 1:1 DMEM:Ham's F12 media supplemented with lutein crystals (Sigma-Aldrich, St. Louis, MO, USA) was prepared. Lutein crystals were dissolved in 0.05% dichloromethane solution at a final concentration of 1 μg/mL, as described in the literature [19]. ARPE-19 cell cultures were serum-starved for 24 h and then pre-treated with lutein-supplemented media. The following day were exposed to light.

Light source and blue light filter setup
Controlled exposure of RPE cells to white light was achieved using a cell culture incubator that enabled the installation of a fixed light source (white light LED, NSSW157AT, Nichia Corporation, Japan). In order to set up the third treatment condition, a blue light filter (BLF) (R4590, Roscolux, USA; 98% blocking at 450 nm) was placed between the cell culture plate and the light source. The intensity of light reaching the surface of the cell culture plates was then measured using a luxometer and found to be an average of 9000 lx (range: 8800–9200 lx). In the group exposed to white light without a BLF, a series of transparent filters were used to reduce the intensity of light at the surface of cell culture plates to within the range measured for the group with the BLF.

Angiogenesis arrays
Quantification of angiogenic cytokines within the collected supernatant was performed as per the manufacturer’s instructions using the Quantibody Human Angiogenesis Array 1 kit (RayBiotech Inc., Norcross, GA, USA), which is based on a sandwich enzyme-linked immunosorbent assay-based system. The array allows for the simultaneous quantification of the following 10 pro-angiogenic cytokines: angiogenin, ANG-2, EGF, bFGF, HB-EGF, PDGF-BB, Leptin, PIGF, HGF, and VEGF-A. Briefly, protein secretion levels of the angiogenic cytokines within the samples were analyzed by comparing the intensities of the fluorescent signals produced with the standard curve generated by standard samples in each array. Concentrations were reported in picograms per milliliter (pg/mL). A step-by-step methodology of this process has previously been described by our group [20].

Statistical analysis
Shapiro-Wilk test was used to assess normal distributions in the levels of angiogenic factors and comparisons were performed with the Student’s t-test or Wilcoxon rank sum test, as appropriate. For comparison of two experimental groups, an unpaired, two-sample Welch’s t-test was used. To compare the three experimental groups, the nonparametric Kruskal-Wallis test was used, followed by Dunn’s post hoc test to calculate the p-value for each group. Graphs show the mean ± standard error of the mean (SEM); statistical significance was defined as p < 0.05. All analyses were performed using GraphPad Prism statistical software (GraphPad Software, Inc., San Diego, CA, USA).

Results
The effect of white light exposure on the secretion of angiogenic cytokines by ARPE-19 cells was determined in three experiments. Only three of the ten cytokines analyzed were above the lower limit of detection for the assay, namely angiogenin, bFGF, and VEGF.

On the first experiment, a significant (p < 0.05) decrease was observed in angiogenin secretion levels following white light exposure (compared to dark conditions). Increases in both bFGF and VEGF were observed when RPE cells were exposed to white light compared to dark conditions (normoxia); however, only the increase in bFGF was significant (p < 0.05). The effect of blue light filtering was also assessed. A significant (p < 0.05) increase in angiogenin levels was observed within supernatant samples collected from RPE cells exposed to white light with a BLF compared to samples collected from RPE cells exposed to white light without a BLF. Light-induced secretion of bFGF was decreased in RPE cells exposed to white light in the presence of a BLF compared to cells exposed to white light alone; however, this finding was not statistically significant. Although a slight decrease in VEGF levels was observed with blue light filtering compared to white light exposure, this decrease was also not statistically significant (Fig. 1).

On the second experiment, it was determined whether the effects of BLFs on the secretion of angiogenin, bFGF, and VEGF were maintained under hypoxic conditions. As seen under normoxic conditions, a significant (p < 0.05) decrease in angiogenin levels was observed upon white light exposure compared to dark conditions. A slight increase in angiogenin levels was seen when RPE cells were exposed to white light with a BLF; however, this was not found to be significant. In addition, a decrease in light-induced bFGF and VEGF secretion was observed with blue light filtering; however, these findings were also statistically insignificant (Fig. 2).

On the third experiment, the effect of blue light filtering was also assessed when the cells under normoxic conditions were pre-treated with lutein. Trends in the secretion of angiogenin, bFGF, and VEGF following lutein pretreatment were similar to those observed when RPE cells were grown under hypoxic and normoxic conditions; however, none of the trends were found to be significant (Fig. 3).
Discussion
In the present study, we investigated the effects of blue light filtering on the secretion profile of proangiogenic cytokines by RPE cells. To the best of our knowledge, this is the first study to demonstrate that following light exposure, angiogenin secretion by RPE cells is decreased, and this decrease is abrogated with a blue light filter. We also demonstrated that, although not significant, this trend is maintained when RPE cells are grown under hypoxic conditions and when pre-treated with lutein.

Although the etiology of AMD is not well understood, there is strong evidence indicating that retinal hypoxia plays a significant role in retinal neovascularization [21, 22]. On the other hand, lutein-containing supplements have been found to be beneficial and protective in slowing the progression of AMD [23–26]. We therefore sought to determine whether the effects of blue light filtering are maintained when RPE cells are exposed to hypoxic conditions or when pre-treated with lutein. We focused our investigation on angiogenin, VEGF, and bFGF given that their secretion was found to be above the limit of detection as indicated by our array system.
The role of angiogenin in the aging eye and in choroidal neovascularization is poorly understood. One study evaluating the histopathologic secretion of angiogenin in postmortem control and AMD donor eyes noted similar secretion patterns, however no conclusive statement can be reached given the small sample size of three AMD eyes used in the analyses [27]. Results from studies assessing angiogenin levels in other ocular malignancies, namely diabetic retinopathy (DR), have been contradicting. Marek et al. (2011) described an inverse relationship in the concentrations of VEGF and angiogenin in patients with DR [28]. The authors observed a decrease in angiogenin and an increase in VEGF concentrations in both serum and vitreous samples from patients with DR compared to healthy individuals [28]. This is in accordance with our results demonstrating an inverse relationship between VEGF and angiogenin secretion levels following light exposure. Our group has also previously demonstrated an upregulation in angiogenin secretion with an expected abrogation in VEGF secretion following anti-VEGF treatment of RPE cells [20]. Our combined results support the hypothesis of a compensatory mechanism that is likely activated in response to decreased VEGF levels. To the best of our knowledge, this is the first report describing the differential secretion of angiogenin by RPE cells in response to a blue-light filter in vitro. Additional studies evaluating the secretion pattern of angiogenin in normal and AMD eyes, and the mechanisms underlying its down-regulation by RPE cells following light exposure are required.

Our results also demonstrated that blue light filters prevent light-induced up-regulation of bFGF and VEGF secretion to near normal levels. Although not significant, this trend is also observed when RPE cells are grown under hypoxic conditions and when pre-treated with lutein prior to exposure to experimental conditions. Unlike angiogenin, the proangiogenic effects of VEGF and bFGF in ocular neovascularization are well documented in the literature [12, 29–33]. It is also well established that VEGF and bFGF levels are increased in hypoxic conditions as a means of promoting neovascularization of ischemic tissues [34–36]. Our data on VEGF secretion are in accordance with previous reports demonstrating VEGF up-regulation by RPE cells following light exposure and its inhibition when cells are cultured with a blue light-filtering intraocular lens [37].

A recent study by Kishimoto et al. (2005) was first to describe the interplay between VEGF, bFGF, and angiogenin [38]. The authors demonstrated the important role that angiogenin plays in mediating VEGF- and bFGF-induced angiogenesis. Specifically, the authors showed that angiogenin is indeed required for VEGF and bFGF to stimulate angiogenesis [38]. In our study, we observed no changes compared to control in light-induced secretion of VEGF and bFGF with a blue light filter; however, there was a concomitant increase in angiogenin production. Thus, we hypothesize that RPE cells increase angiogenin secretion as a means to compensate for the protective effects of blue light filters. As anti-VEGF therapy is the gold standard treatment for neovascular AMD, it may be of value to further investigate the effect of anti-VEGF treatment on angiogenin secretion and action in the eye.

The detrimental effects of blue light on the viability of RPE cells are well documented in vitro and in vivo [39–44]. Blue light filters have been shown to protect RPE cells from light-induced damage and apoptosis in RPE cell cultures [10, 11, 45]. To the best of our knowledge, this is the first study investigating the secretion of pro-angiogenic cytokines by blue-light exposed RPE cells under normoxia, hypoxia, and lutein-pretreated conditions. Our findings complement the growing body of evidence on the protective effects of blue light filtering IOLs, and suggest that these benefits may be maintained even when patients have dry AMD and are consuming lutein-containing supplements. It should be noted that the current study is not without limitations, and the previous statements require confirmation through additional in vitro and in vivo studies. For one, the light source used in our study yielded a range of light intensity albeit narrow, and may not mimic life-long exposure to blue light. Experts differ as to the exact wavelength of blue light; therefore it is difficult to be accurate when intending to block this specific wavelength range. Despite utilizing a yellow filter almost selective in blocking blue light, we must assume that minimal percentage of green light was also blocked, which we recognize as a limiting factor of our study. Another limitation of our study is the total number of replicates that may have prevented the attainment of statistically significant data points.

Conclusions
Our findings support the position that blue light filtering affects the secretion of angiogenic factors by RPE cells under normoxic, hypoxic, and lutein-pretreated conditions in a similar manner. These results support growing evidence on the protective effects of blue light filtering IOLs and suggest that blocking effect on the blue wavelength light may be a benefit in patients with non-exudative AMD, also when consuming lutein-containing supplements. The cellular responses of RPE cells following blue light exposure warrants further investigation.

Abbreviations
AMD: Age-related macular degeneration; ANG-2: Angiopoietin; AREDS2: Age-related eye disease study 2; bFGF: Basic fibroblast growth factor; BLF: Blue light filter; DMEM: Dulbecco’s modified eagle’s medium; DR: Diabetic retinopathy; EGF: Epidermal growth factor; FBS: Fetal bovine serum; HB-EGF: Heparin-binding EGF-like growth factor; HGF: Hepatocyte growth factor; IOLs: Intraocular lenses; PDGF-BB: Platelet-derived growth factor; PIGF: Placental growth factor; RPE: Retinal pigmented epithelial cells; SEM: Standard error of the mean; UV: Ultraviolet; VEGF: Vascular endothelial growth factor.
Acknowledgements
We greatly appreciate Xavier Millán for statistical analysis support and Tiffany Porracio for the technical assistance.

Funding
Natalia Vilá is supported by a research grant from Fundación Alfonso Martin Escudero (FAME).

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Authors’ contributions
NV conception and design, conducting the experiment, acquisition of data, data interpretation and drafting the manuscript. AS data interpretation and drafting the manuscript. VBF acquisition of data and conducting the experiment. PZ acquisition of data and conducting the experiment. SA acquisition of data and conducting the experiment. PL drafting the manuscript. LA conception and design. MNB conception and design. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 1 October 2016 Accepted: 25 October 2017
Published online: 02 November 2017

References
1. Gehrs KM, Anderson OH, Johnson LV, Hageman GS. Age-related macular degeneration—emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38(7):450–71.
2. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640–2.
3. West SK, Rennert HL, Bressler NM, et al. Exposure to sunlight and other risk factors for age-related macular degeneration. Arch Ophthalmol. 1989;107(6):875–9.
4. Blasik J, Petrovski G, Varek Z, Facikova A, Kaarniranta K. Oxidative stress, hypoxia, and autophagy in the neovascular processes of age-related macular degeneration. Biomed Res Int. 2014;2014:768026.
5. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45(2):115–34.
6. Cruickshanks KJ, Klein R, Klein BK. Sunlight and age-related macular degeneration: the Beaver dam eye study. Arch Ophthalmol. 1993;111(4):514–8.
7. Klein R, Klein BE, Jensen SC, Meuer SM. The Five-year Incidence and Progression of Age-related Maculopathy. The Beaver Dam Eye Study. 1997; 104(1):7–21.
8. Mainster MA. Light and macular degeneration: a biophysical and clinical perspective. Eye (Lond). 1987;1(2):304–10.
9. Bressler NM, Bressler SB, West SK, Fine SL, Taylor HR. The grading and prevalence of macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol. 1989;107(6):847–52.
10. Kernt M, Neubauer AS, Liegl R, Ebli KH, Alge CS, Lackerbauer CA, Ulbig MW, Kampik A. Cytoprotective effects of a blue light-fitting intracocular lens on human retinal pigment epithelium by reducing phototoxic effects on vascular endothelial growth factor-alpha, Bax, and Bcl-2 expression. J Cataract Refract Surg. 2009;35(2):354–62.
11. Sparrow JR, Miller AS, Zhou J. Blue light-absorbing intracanal lens and retinal pigment epithelium protection in vitro. J Cataract Refract Surg. 2004;30(4):873.
12. Yanagi Y, Inoue Y, Iriyama A, Jang W-D. Effects of yellow intracanal lenses on light-induced upregulation of vascular endothelial growth factor. J Cataract Refract Surg. 2006;32(9):1540–4.
13. Grunwald JE, Metelitsina T, Dupont JC, Ying GS, Maguire MG. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci. 2005;46(3):1033–8.
14. Arjamoo A, Nikinmaa M, Salminen A, Kaarniranta K. Regulatory role of HIF-1α in the pathogenesis of age-related macular degeneration (AMD). Ageing Res Rev. 2009;8(4):349–58.
15. Stefansson E, Geirisdottir A, Sigurdsson H. Metabolic physiology in age-related macular degeneration. Prog Retin Eye Res. 2011;30(1):72–80.
16. Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015;4967–81.
17. Snodderly DM, Auran JD, Delori FC. The macular pigment. II. Spatial distribution in primate retinas. Invest Ophthalmol Vis Sci. 1984;25(6):74–85.
18. Snodderly DM, Brown PK, Delori FC, Auran JD. The macular pigment. I. Absorbance spectra, localization, and discrimination from other yellow pigments in primate retinas. Invest Ophthalmol Vis Sci. 1984;25(6):660–73.
19. Age-Related Eye Disease Study 2 Research G, Chew EY, Clemons TE, Muntz DR, Jensen S, Klein BR, Manges PJ, Martin W, et al. Age-Related Eye Disease Study 2 Research G. AREDS2 report no. 3. JAMA Ophthalmol. 2014;132(2):142–9.
20. Ganner T, Maloney S, Antecka E, Coeera JA, Burnier MN Jr. 3,4-dihydroxyphenyl ethanol reduces secretion of angiogenin in human retinal pigment epithelial cells. Br J Ophthalmol. 2013;97(3):371–4.
21. Inoue Y, Yanagi Y, Matsusara K, Takahashi H, Tamaki Y, Arai M. Expression of hypoxia-inducible factor-1α and 2α in choroidal neovascular membranes associated with age-related macular degeneration. Br J Ophthalmol. 2007;91(12):1720–1.
22. Mousa SA, Lorelli W, Campochiaro PA. Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells. J Cell Biochem. 1999;74(1):135–43.
23. Kirnyski NI, Landrum JT, Bone RA. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Annu Rev Nutr. 2003;23(1):171–201.
24. Maers-Perlman JA, Millen AE, Ficek TL, Hankinson SE. The body of evidence emerging pathogenetic and therapeutic concepts. Ann Med. –2011;43(10):819–25.
25. Koh H-H, Murray IJ, Nolan D, Carden D, Feather J, Beatty S. Plasma and macular responses to lutein supplement in subjects with and without age-related maculopathy: a pilot study. Exp Eye Res. 2004;79(1):121–7.
26. Murray U, Makridaki M, van der Veen RLP, Carden D, Parry NRA, Berendschot TTJM. Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR StudyEffetct of Lutein supplementation on visual acuity. Invest Ophthalmol Vis Sci. 2013;54(3):1781–8.
27. Skeie JM, Zeng S, Faldley EA, Mullins RF. Angiogenin in age-related macular degeneration. –2011;21(1):232–3.
28. Marek N, Raczyńska K, Siebert J, Myśliwiec M, Zorea K, Myśliwska J, Reiber-Gostomskia M, Trzonkowski P. Decreased angiogenin concentration in vitreous and serum in proliferative diabetic retinopathy. Microvasc Res. 2011;82(1):1–5.
29. O’Driscoll C, O’Connor J, O’Brien CJ, Cotter TG. Basic fibroblast growth factor-induced protection from light damage in the mouse retina in vivo. J Neurochem. 2008;105(2):524–36.
30. Xu W, Wang X, Xu G, Guo J. Light-induced retinal injury enhanced neurotrophins secretion and neurotrophic effect of mesenchymal stem cells in vitro. Arq Bras Oftalmol. 2013;76(2):205–10.
31. Frank RN, Amin RH, Elliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol. 1996;122(3):393–403.
32. Spilsbury K, Garrett KL, Shen W-Y, Constable IJ, Rakoczey PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol. 2000;157(1):35–44.
33. Wong CG, Rich KA, Liaw L-HL, Hsu HT, Berns MW. Intravitreal VEGF and bFGF produce flridal retinal neovascularization and hemorrhage in the rabbit. Curr Eye Res. 2001;22(2):140–7.
34. Calvani M, Rapisarda A, Uranchimeg B, Shoemaker RH, Melillo G. Hypoxic induction of an HIF-1α-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood. 2006;107(7):2705-12.

35. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest. 1995;72(6):638-45.

36. Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, Samardzija M, Bauer C, Gassmann M, Remé CE. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med. 2002;8(7):718-24.

37. Zhou J, Cai B, Jang YP, Pachydaki S, Schmidt AM, Sparrow JR. Mechanisms for the induction of HNE-MDA-and AGE-adducts, RAGE and VEGF in retinal pigment epithelial cells. Exp Eye Res. 2005;80(4):567-80.

38. Kishimoto K, Liu S, Tsuji T, Olson KA, GF H. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene. 2005;24(3):445-56.

39. Sparrow JR, Nakanishi K, Parish CA. The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells. Invest Ophthalmol Vis Sci. 2000;41(7):1981-9.

40. Ham WT, Mueller HA, Sliney DH. Retinal sensitivity to damage from short wavelength light. 1976.

41. Busch EM, Gorgels TGMF, van Norren D. Temporal sequence of changes in rat retina after UV-A and blue light exposure. Vis Res. 1999;39(7):1233-47.

42. Putting BJ, Van Best JA, Vreven G, Oosterhuis JA. Blue-light-induced dysfunction of the blood-retinal barrier at the pigment epithelium in albino versus pigmented rabbits. Exp Eye Res. 1994;58(1):31-40.

43. Remé CE, Weller M, Szczesny P, Munz K, Häfezi F, Reinboth J-J, Clausen M. Light-induced apoptosis in the rat retina in vivo. Degenerative diseases of the retina. p. 193-8.

44. Crockett RS, Lawwell T. Oxygen dependence of damage by 435 nm light in cultured retinal epithelium. Curr Eye Res. 1984;3(1):209-22.

45. Rezaei KA, Gasyna E, Seagle B-L, Norris JR, Rezaei KA. AcrySof natural filter decreases blue light-induced apoptosis in human retinal pigment epithelium. Graefes Arch Clin Exp Ophthalmol. 2008;246(5):671-6.